| MeSH term | MeSH ID | Detail |
|---|---|---|
| Edema | D004487 | 152 associated lipids |
| Precancerous Conditions | D011230 | 48 associated lipids |
| Postoperative Complications | D011183 | 5 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Surgical Wound Infection | D013530 | 7 associated lipids |
| Neoplasm Recurrence, Local | D009364 | 5 associated lipids |
| Osteonecrosis | D010020 | 5 associated lipids |
| Hypotension | D007022 | 41 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Stoller G et al. | An 11.8 kDa proteolytic fragment of the E. coli trigger factor represents the domain carrying the peptidyl-prolyl cis/trans isomerase activity. | 1996 | FEBS Lett. | pmid:8612805 |
| Márquez JA and Serrano R | Multiple transduction pathways regulate the sodium-extrusion gene PMR2/ENA1 during salt stress in yeast. | 1996 | FEBS Lett. | pmid:8612770 |
| Galat A | A note on circular-dichroic-constrained prediction of protein secondary structure. | 1996 | Eur. J. Biochem. | pmid:8612612 |
| Brousse N and Goulet O | Small bowel transplantation. | 1996 | BMJ | pmid:8611766 |
| Furth S et al. | Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. | 1996 | Pediatr. Nephrol. | pmid:8611359 |
| Johnson MW et al. | Hepatitis C viral infection in liver transplantation. | 1996 | Arch Surg | pmid:8611094 |
| Osowski CL et al. | Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. | 1996 | Transplantation | pmid:8610430 |
| Cacciarelli TV et al. | Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. | 1996 | Transplantation | pmid:8610416 |
| Hariharan S et al. | Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. | 1996 | Transplantation | pmid:8610411 |
| Yanchar NL et al. | Tacrolimus (FK506)--its effects on intestinal glucose transport. | 1996 | Transplantation | pmid:8610392 |
| Singh N et al. | Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. | 1996 | Transplantation | pmid:8610349 |
| Peters KP et al. | The automatic search for ligand binding sites in proteins of known three-dimensional structure using only geometric criteria. | 1996 | J. Mol. Biol. | pmid:8609611 |
| Esquivel CO et al. | Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. | 1996 | Transplantation | pmid:8607198 |
| Busuttil RW et al. | General guidelines for the use of tacrolimus in adult liver transplant patients. | 1996 | Transplantation | pmid:8607197 |
| Suzuki S et al. | Pure red cell aplasia induced by FK506. | 1996 | Transplantation | pmid:8607191 |
| Greeno EW et al. | Exchange transfusion the hard way: massive hemolysis following transplantation of bone marrow with minor ABO incompatibility. | 1996 | Transfusion | pmid:8607158 |
| Fay JW et al. | FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. | 1996 | Blood | pmid:8605372 |
| Murao K et al. | Immunosuppressant agent FK506 stimulates growth hormone (GH) secretion and gene expression of hypothalamic GH-releasing hormone in the rat. | 1996 | Endocrinology | pmid:8603582 |
| Vilquin JT et al. | Partial laminin alpha2 chain restoration in alpha2 chain-deficient dy/dy mouse by primary muscle cell culture transplantation. | 1996 | J. Cell Biol. | pmid:8601607 |
| Lake KD and Canafax DM | Important interactions of drugs with immunosuppressive agents used in transplant recipients. | 1995 | J. Antimicrob. Chemother. | pmid:8601538 |
| Rifai N et al. | The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines. | 1996 | Clin. Biochem. | pmid:8601324 |
| Gruessner RW et al. | A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. | 1996 | Transplantation | pmid:8600635 |
| Inomata Y et al. | The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. | 1996 | Transplantation | pmid:8600632 |
| Beretta L et al. | Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. | 1996 | EMBO J. | pmid:8599949 |
| Ma J et al. | Rectification of skeletal muscle ryanodine receptor mediated by FK506 binding protein. | 1995 | Biophys. J. | pmid:8599646 |
| Dan Y et al. | IL-3 augments TCR-mediated responses of type 2 CD4 T cells. | 1996 | J. Immunol. | pmid:8598473 |
| Hammond TG and Kind CN | Pancreatic and nephrotoxicity of immunomodulator compounds. | 1995 | Toxicol. Lett. | pmid:8597171 |
| Taylor PJ et al. | Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. | 1996 | Clin. Chem. | pmid:8595724 |
| Sakane T et al. | [A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions]. | 1995 | Ryumachi | pmid:8594659 |
| Dhar DK et al. | FK506 maintains cellular calcium homeostasis in ischemia-reperfusion injury of the canine liver. | 1996 | J. Surg. Res. | pmid:8592405 |
| Cardenas ME et al. | Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. | 1995 | Curr. Opin. Nephrol. Hypertens. | pmid:8591053 |
| Lohse DL et al. | Insights derived from the structures of the Ser/Thr phosphatases calcineurin and protein phosphatase 1. | 1995 | Structure | pmid:8590008 |
| Jusko WJ et al. | Consensus document: therapeutic monitoring of tacrolimus (FK-506). | 1995 | Ther Drug Monit | pmid:8588229 |
| McMaster P et al. | Therapeutic drug monitoring of tacrolimus in clinical transplantation. | 1995 | Ther Drug Monit | pmid:8588228 |
| Jusko WJ | Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. | 1995 | Ther Drug Monit | pmid:8588227 |
| Fung JJ and Starzl TE | FK506 in solid organ transplantation. | 1995 | Ther Drug Monit | pmid:8588226 |
| Thomson AW et al. | Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. | 1995 | Ther Drug Monit | pmid:8588225 |
| Soldin SJ | Receptor (immunophilin-binding) assay for immunosuppressive drugs. | 1995 | Ther Drug Monit | pmid:8588223 |
| Goodall T et al. | FK506-induced endothelin release by cultured rat mesangial cells. | 1995 | J. Cardiovasc. Pharmacol. | pmid:8587453 |
| Takeda Y et al. | Effect of FK 506 on the expression of endothelin receptor mRNA in the vasculature. | 1995 | J. Cardiovasc. Pharmacol. | pmid:8587392 |
| Büttemeyer R et al. | Peripheral nerve allograft transplantation with FK506: functional, histological, and immunological results before and after discontinuation of immunosuppression. | 1995 | Ann Plast Surg | pmid:8585683 |
| Gonschior AK et al. | Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. | 1995 | Ther Drug Monit | pmid:8585114 |
| Hemenway CS et al. | vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(+)-ATPase assembly. | 1995 | Genetics | pmid:8582630 |
| Sekigawa I et al. | Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120. | 1995 | J. Clin. Immunol. | pmid:8576317 |
| Wesselborg S et al. | Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). | 1996 | J. Biol. Chem. | pmid:8576111 |
| Sano T et al. | FK506 and cyclosporin A inhibit granulocyte/macrophage colony-stimulating factor production by mononuclear cells in asthma. | 1995 | Eur. Respir. J. | pmid:8575571 |
| Vilquin JT et al. | FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. | 1995 | Hum. Gene Ther. | pmid:8573612 |
| Castillo Lugo JA | Clinical and experimental immunosuppression. | 1995 May-Jun | Bol Asoc Med P R | pmid:8573248 |
| Charters AR et al. | Developmental expression of FK506 binding proteins and calcineurin in rat brain. | 1995 | Biochem. Soc. Trans. | pmid:8566310 |
| Tanida I et al. | Yeast Cls2p/Csg2p localized on the endoplasmic reticulum membrane regulates a non-exchangeable intracellular Ca2+ pool cooperatively with calcineurin. | 1996 | FEBS Lett. | pmid:8566225 |